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Subsyndromal Symptomatic Depression (SSD), or subthreshold depression, 
affects roughly 15% of community-dwelling older adults and puts them at increased risk 
for developing Major Depressive Disorder (MDD), which represents a risk factor for 
Alzheimer’s Disease (AD) and may expedite disease progression. While the relationship 
between MDD and AD has been well established, the interaction between SSD and 
cognitive functioning has not been explored in depth. Further, clinicians have long 
postulated that depression is not a monolithic disorder but rather a group of disorders 
which are heterogeneous in onset, symptoms, course, and treatment. One hundred and six 
participants, 65 and older were recruited as part of the Adventist Health Study-2 
Cognition and Neuroimaging Substudy and underwent comprehensive 
neuropsychological testing. Results of an independent samples t-test revealed that 
individuals who met criteria for SSD performed significantly worse in the immediate 
recall over five learning trials on the Rey Auditory Verbal Learning Test (RAVLT) than 
individuals who did not report depressive symptomatology. Further, a hierarchical 
regression analysis evidenced that depressive symptoms categorized as “hopelessness”, 
“dysphoric mood”, and “cognitive impairment” were significant predictors of global 
cognitive functioning within our SSD sample. These findings suggest that SSD—
 
x 
specifically when symptoms are related to “hopelessness”, “dysphoric mood”, and 
“cognitive impairment”—has a significant impact on cognition. Future research should 
utilize a longitudinal study design that examines conversion rates of SSD to 
MCI/dementia to conclude that SSD represents a clinical marker of dementia. If 
identified as a viable clinical marker, early detection and treatment of SSD could 
potentially prevent worsening of depression symptoms as well as delay—or even curb—




INTRODUCTION TO DEMENTIA 
 
Dementia can be defined as a group of symptoms which are characterized by a 
loss in cognitive functioning which significantly impacts one’s day-to-day activities 
(Schoenberg & Scott, 2011). While there are several different types of dementias which 
are classified by etiology and presenting symptoms, the most common and colloquially 
known form is Alzheimer’s Disease (AD). AD accounts for roughly 50% of all dementia 
cases with 35% being the sole result of AD pathology while another 15% is due to mixed 
pathologies of both AD and Vascular Dementia (Schoenberg & Scott, 2011). The 
majority of those diagnosed are over the age of 65 and exhibit severe memory and 
functional impairments. In the United States, nearly 5 million individuals are living with 
AD and estimates suggest this will increase to 14 million by 2050, highlighting the 
significance and a pressing need to increase our understanding of its cause and course 
(Hebert, Weuve, Scherr, & Evans, 2013). While AD is not fully understood, it is believed 
that the course of the disease begins with a prodromal period that begins approximately 
20 years before any noticeable cognitive deficits emerge (Shaw et al., 2009). However, 
by the time these deficits manifest, the neurodegeneration is often considered too severe 
to respond to current therapies. Therefore, efforts have been made to understand and 
identify the underlying pathology as well as other risk factors before extensive 
neurodegeneration has taken place in the hopes of early intervention. To understand AD, 
many researchers have examined Mild Cognitive Impairment (MCI), which can be 
defined as an intermediary state between normal aging and AD (Schoenberg & Scott, 
2011). Specifically, researchers have examined potential biological markers which may 
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predict conversion from MCI to AD. 
 
Efforts to Detect the Prodromal Stages of Alzheimer’s Disease 
 
Mild Cognitive Impairment 
 Mild Cognitive Impairment (MCI) describes individuals who are in an 
intermediate state between normal aging and dementia (Schoenberg & Scott, 2011). 
Typically, the MCI patient will exhibit deficits in at least one cognitive domain (1.5 or 
more standard deviations below the age-adjusted mean) and may present with memory 
complaints but exhibit no significant impairments in their daily functioning (Petersen et 
al., 2001). Within MCI, there are several different subtypes which can be categorized as 
amnestic or nonamnestic as well as single-domain or multiple domain impairments. 
Amnestic MCI involves impairments in the domain of memory while non-amnestic MCI 
involves impairments in other non-memory domains. Single-domain indicates that the 
individual is only experiencing significant impairments in one cognitive domain while 
multiple domain is indicative of multiple domain impairments (Petersen et al., 2001). It 
has been theorized that specific MCI subtypes may predict the type of dementia that the 
patient converts to. For example, amnestic MCI patients might be more likely to progress 
to AD while a non-amnestic MCI patient exhibiting executive deficits might be more 
inclined to develop Frontotemporal Dementia (Schoenberg & Scott, 2011). However, the 
current research indicates that these patterns of progression aren’t as clear cut (Kondo et 
al., 2016; Luis et al., 2004; Manly et al., 2008). Aside from differential patterns of 
cognitive deficits, past research has indicated that specific neuropsychiatric symptoms 
 
3 
may be more representative of different types of dementia. For instance, delusions may 
be more characteristic of AD, while depression is more common in vascular dementia, 
and hallucinations are more prevalent in dementia with Lewy bodies (Chiu, Tsai, Chen, 
Chen, & Lai, 2016; Lyketsos et al., 2000). Therefore, examining neurocognitive profiles 
in conjunction with neuropsychiatric symptoms may have greater predictive value when 
categorizing dementia than by MCI subtype alone.  
 
Structural Imaging 
The medial temporal lobe, specifically the hippocampus, plays an important role 
in the consolidation of memory. It is also the location of the earliest neurofibrillary 
pathology associated with AD (Schoenberg & Scott, 2011). With this in mind, Jack et al. 
(1999) conducted a longitudinal study examining hippocampal volume in MCI patients as 
a possible predictor of conversion to AD. Specifically, they wanted to determine whether 
or not Magnetic Resonance Imaging (MRI) techniques could be used to predict 
conversion to AD in MCI patients above and beyond the effects of age, apolipoprotein E 
(APOE) genetic risk factors, hypertension, cognitive performance, and heart disease. 
Results indicated that smaller hippocampal volume at baseline predicted an increased 
likelihood of converting to AD from MCI at a 3-year follow up, lending support to the 
predictive power of structural imaging techniques when detecting early stages of AD.  
 
Functional Imaging 
With MRI and other structural imaging techniques established as useful measures 
in identifying AD biological markers, Mosconi et al. (2004) investigated whether 
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functional imaging techniques could be used to predict conversion from MCI to AD. 
Specifically, they wanted to examine whether fluoro-2-deoxy-d-glucose (FDG) Positron 
Emission Tomography (PET) measures with the Apolipoprotein E (APOE) genotype 
would be useful in determining whether an MCI patient was at an increased risk of 
converting to AD. The APOE E4 allele is believed to be the most common susceptibility 
gene for AD while APOE E2 is believed to have protective qualities against AD (Corder 
& Caskey, 2009). Those who converted to AD from MCI had lower metabolic activity in 
the parietal regions of the brain, specifically in the Inferior Parietal Lobule, establishing 
that functional imaging techniques could be useful predictors of AD conversion. Further, 
an interaction between APOE E4 and glucose metabolism appeared to indicate that MCI 
patients who were carriers of the APOE E4 allele presented with even greater reductions 
in metabolic activity.  
 
Cerebrospinal Fluid 
The hallmark pathological features of AD are neurofibrillary tangles and amyloid 
beta (AB) plaque buildups which typically begin in the hippocampus. Specifically, these 
buildups are the result of AB peptides 1 – 42, which are the least soluble of the known 
AB peptides (Schoenberg & Scott, 2011). In an attempt to establish a cerebrospinal fluid 
(CSF) marker of AD, Shaw et al. (2009) compared AB1-42 CSF levels in a sample of 
MCI, non MCI, and AD autopsy confirmed patients. Results of their study concluded that 
CSF AB1-42 was a reliable biomarker in predicting AD with an overall test accuracy of 





 While biological markers are useful for identifying prodromal stages of 
AD/Dementia, the most reliable predictor of conversion from MCI to AD is 
comprehensive neuropsychological testing. Using a longitudinal design, Tabert et al. 
(2006) evaluated conversion rates of MCI to AD to identify specific patterns of deficits 
that predict conversion. A comprehensive battery including measures of learning and 
memory, orientation, abstract reasoning, language, attention, and visuospatial ability was 
compiled. After three years, 26% of the sample converted to AD from MCI and 50% of 
those who converted qualified as MCI multiple-domain amnestic patients. When 
examining specific patterns in the neuropsychological profiles, percent savings from 
immediate to delayed recall on a test of verbal learning and memory (Selective 
Reminding Test, SRT) was the strongest predictor of conversion. On the SRT, percent 
savings describes the number of words recalled after the delay as a proportion of the 
words recalled before the delay. In addition, an indirect measure of executive function 
(WAIS-R digit symbol coding), semantic verbal fluency (Animals), and confrontation 
naming (Boston Naming Test) also predicted conversion. However, after all predictors 
were added into a single model, only measures of verbal learning and memory and 
executive function remained statistically significant. These findings, specifically the 
deficits in executive function and verbal learning and memory, corroborate previous 
research which has found similar patterns of deficits in the AD patient (Albert, Moss, 
Tanzi, & Jones, 2001). While deficits in verbal fluency and confrontation naming are 
often seen in AD patients, these specific patterns of deficits become more apparent as the 
disease progresses, which might explain why they were not statistically significant 
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deficits in this sample of early converts (Schoenberg & Scott, 2011). Regarding the 
limitations of this study, a measure specifically designed to assess executive function was 
not utilized. Therefore, future research examining neuropsychological profiles of MCI to 
AD converts should include specific tests to assess this domain.  
 
Risk Factors 
While biological markers such as hippocampal neurodegeneration, inferior 
parietal lobule metabolism, and AB1-42 CSF levels and clinical markers such as 
executive and memory deficits are useful in identifying early stages of AD, there is no 
“gold standard” for early identification. In reality, a combination of these markers is most 
likely the best predictor of MCI to AD conversion. However, there are some who argue 
that MCI is in fact an early stage of AD/Dementia (Morris & Cummings, 2005). 
Therefore, while identification of biological/clinical markers that predict conversion are 
useful and offer greater insight into the cause of AD, examination of the risk 
factors/prodromal stages before the onset of MCI might prove more useful in terms of 
prevention/intervention. Currently, several risk factors of AD have been identified, 
including: age, female gender, lower levels of education, history of head injury, APOE4, 
and a history of neuropsychiatric illness (Schoenberg & Scott, 2011; Van der Mussele et 
al., 2013). Most research on neuropsychiatric illness and dementia has examined 
depression. This is due to the frequency that major depressive disorder (MDD) co-occurs 
with dementia. Currently, it is estimated that 20% of all dementia cases have a comorbid 





DEPRESSION AND DEMENTIA 
 
While the connection between major depressive disorder (MDD) and AD is 
undisputed, the exact nature of the relationship remains unclear. While there is some 
evidence that suggests that MDD is an independent risk factor for AD, other research 
seems to indicate that it is a prodromal symptom of the disease (Barnes et al., 2012; 
Ownby, Crocco, Acevedo, John, & Loewenstein, 2006). Currently, the consensus on the 
matter is that MDD in younger adulthood represents an independent risk factor, while 
depression that first occurs later in life may be a prodromal symptom of AD. MDD, 
which is often characterized by a depressed mood and loss of interest in activities, is 
recognized as the leading cause of life-time disability and is estimated to have a 3-month 
prevalence rate of 7% in the general population and 3-5% in the elderly population 
(Anstey, von Sanden, Sargent-Cox, & Luszcz, 2007; Chisholm, Sanderson, Ayuso-
Mateos, & Saxena, 2004; Diagnostic and statistical manual of mental disorders: DSM-
5™., 5th ed, 2013). Further, studies examining the conversion rates of Mild Cognitive 
Impairment to AD found that depressed individuals had a 50% chance of developing AD 
compared to the 36% conversion rate in the non-depressed group (Lee et al., 2012). This 
relationship was particularly salient in individuals who exhibited deficits in multiple 
cognitive domains (Gabryelewicz et al., 2007; Tabert et al., 2006).  
 
Neuropsychiatric Symptoms 
While a history of neuropsychiatric illness is associated with an increased risk for 
developing dementia (Schoenberg & Scott, 2011), Teng, Lu, and Cummings (2007) 
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conducted a study to further delineate specific neuropsychiatric symptoms that were 
associated with an increased risk for converting from MCI to AD. To assess for 
neuropsychiatric symptoms, the Neuropsychiatric Inventory (NPI) was utilized. The NPI 
is a measure of psychopathology specifically designed to assess for common disturbances 
in dementia patients, including: Delusions, Hallucinations, Dysphoria, Anxiety, 
Agitation, Euphoria, Apathy, Irritability, Disinhibition, and Aberrant Motor Activity 
(Cummings et al., 1994). After a two-year follow up, 23% of the sample converted from 
MCI to AD, 100% of which endorsed neuropsychiatric symptoms at baseline. Further, 
symptoms consistent with Depression and Apathy, which can be considered a symptom 
of MDD (Diagnostic and statistical manual of mental disorders: DSM-5™., 5th ed, 
2013), were the strongest predictors of conversion.  
These findings are consistent with previous longitudinal research examining the 
conversion rates from MCI to AD in depressed populations. In a study conducted by 
Modrego and Ferrández (2004), depressed MCI patients were not only more likely to 
progress to AD but they did so at a much quicker rate. Further, it appeared that the 
depressed MCI patients who converted early on were those who responded poorly to 
antidepressants at baseline while those who did respond exhibited a slower progression. 
This appears to suggest that antidepressants may have a protective effect against the 
deterioration associated with dementia. In another study examining the conversion rates 
of MCI to AD in a depressed sample, MCI subtype was also examined as a possible 
predictor. After a 3-year follow up, results indicated that depressed MCI patients 
converted at a much higher rate, especially MCI patients who exhibited deficits in 
multiple domains of cognitive functioning (Gabryelewicz et al., 2007). These findings are 
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consistent with previous research which has divided MCI patients into different 
subgroups (Tabert et al., 2006).  
However, not all researchers have been able to replicate these findings. When 
Rozzini, Chilovi, Trabucchi, and Padovani (2005) examined MCI to AD conversion rates 
in a sample of depressed and non-depressed MCI patients, they did not find any 
significant differences. In fact, a greater proportion of those in the non-depressed MCI 
sample converted to AD than in the depressed sample. However, the depressed MCI 
sample were also being treated for their depression with a selective-serotonin reuptake 
inhibitor, which recent research has suggested might have some protective effects against 
hippocampal neurodegeneration (Dranovsky & Hen, 2006). Therefore, the lack of 
significant differences in conversion may be due to the neuroprotective effects of the 
antidepressants the depressed sample were taking. While the aforementioned study does 
not support the relationship between depression and dementia, it does offer a glimpse at 
possible therapeutic interventions. 
 
Underlying Mechanisms Connecting MDD to AD 
As for what biological mechanisms may account for the relationship between 
MDD and AD, there is some evidence to suggest some underlying Central Nervous 
System (CNS) pathology, specifically in regions associated with monoamine production 
such as the locus coeruleus, dorsal raphe nucleus, and substantia nigra (Björklund & 
Dunnett, 2007; Michelsen, Prickaerts, & Steinbusch, 2008; Wang, Wang, Wu, Huang, & 
Li, 2017). Dysregulation of the monoamines—which includes dopamine, norepinephrine, 
and serotonin—is frequently implicated in the development of depression (Dean & 
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Keshavan, 2017). Zweig et al. (1988) examined neuronal loss and neurofibrillary tangles 
in AD patients and found that AD patients had greater neuronal loss in the locus 
coeruleus and the dorsal raphe nucleus than in the control group. Further, this relationship 
was even more pronounced in AD patients with a comorbid diagnosis of MDD. Other 
studies examining neuronal loss in the locus coeruelus, substantia nigra, and basal ganglia 
were able to corroborate these findings by determining that AD patients with MDD had 
significantly greater neuronal loss in the locus coeruelus as well as the substantia nigra 
(Förstl, Levy, Burns, Luthert, & Cairns, 1994; Zubenko & Moossy, 1988). These findings 
suggest that MDD and AD may have similar underlying pathology which may account 
for why the two often co-occur.  
There has been research to suggest that excess glucocorticoids, or stress 
hormones, may contribute to the connection between MDD and AD. Disturbances in the 
hypothalamic-pituitary-adrenal axis (HPA), which moderates glucocorticoid activity, 
have been implicated in having a role in MDD (Cowen, 2010). Further, Cushing’s 
disease, which is characterized by excess cortisol levels, is associated with decreases in 
hippocampal volume (Starkman, Gebarski, Berent, & Schteingart, 1992). Longitudinal 
designs examining cortisol levels in patients already diagnosed with AD found that 
higher levels of cortisol predict more rapid cognitive decline (Huang et al., 2009). 
Considering that the hippocampus plays a central role in memory and learning and marks 
the location of early AD pathology, it is possible that excess cortisol levels caused by 
MDD may play a role in the connection to AD. However, researchers have also found 
that MDD patients without AD pathology who display excess cortisol levels exhibit 
cognitive impairments (Hinkelmann et al., 2009). Therefore, whether excess cortisol 
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levels in MDD represents a risk factor for AD or simply a comorbid diagnosis has yet to 
be delineated.  
 
Exacerbation of Disability with Comorbid Diagnoses of MDD and AD 
 The neurodegeneration associated with Alzheimer’s Disease not only leads to 
significant deficits in memory but also in functional ability. As the disease progresses, the 
AD patient begins to lose their ability to complete instrumental activities of daily living, 
such as driving, cooking, or assembling tax records. In later stages, they eventually lose 
their ability to complete more basic activities, such as eating, dressing, and toileting 
(Schoenberg & Scott, 2011). Further, Major depressive disorder is currently recognized 
as the leading cause of lifetime disability in the United States (Chisholm et al., 2004). 
Starkstein, Jorge, Mizrahi, and Robinson (2005) examined the functional and 
psychopathological impact major and minor depression has in patients with AD. They 
found that the presence of minor depression was more frequent at latter stages of AD than 
at earlier stages and that 91% of depressed AD patients reported symptoms of “depressed 
mood”. On measures of self-care, sphincter control, mobility, locomotion, 
communication, social cognition, and social support, patients with comorbid diagnoses of 
AD and depression scored significantly worse than non-depressed AD patients. 
Neuropsychological evaluations found that both major and minor depressed AD patients 
performed significantly worse on a test of visual construction (WAIS-IV Block Design) 
than non-depressed AD patients, however, no significant differences were seen on tests of 
object naming (Boston Naming Test), semantic and verbal fluency (COWAT), verbal 
memory (Buschke Selective Reminding Test), and attention/working memory (WAIS-IV 
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Digit Span). AD patients with MDD also exhibited more severe anxiety, apathy, 
delusions, and parkinsonian symptoms than AD patients with minor depression, 
suggesting that impairments in AD increase as the severity of depression increases.  
While the exact relationship between MDD and AD has yet to be delineated, the 
connection between the two is undeniable. Not only has MDD been identified as a risk 
factor/prodromal stage of AD, depression appears to expedite AD decline and exacerbate 
the functional disability associated with AD. Examination of CNS pathology and the 
shared underlying mechanisms may partially explain this connection. Considering the 
modest prevalence rates of MDD and its connection to AD, research examining the 
treatment of depression in relation to dementia may have some positive implications for 
the treatment/prevention of AD. However, in the interest of prevention, examination of 
the intermediary or prodromal stages of MDD and AD/MCI will most likely have more 
of an impact on intervention and treatment development than an exploration of the latter 





HETEROGENEITY OF MAJOR DEPRESSIVE DISORDER 
 
Over the past few decades, Major depressive disorder (MDD) has emerged as one 
of the most prominent mental health disorders and critical public health concern. 
Currently, MDD is the leading cause of life-time disability and the fourth leading 
contributor to the global burden of disability worldwide (Chisholm et al., 2004). 
However, our understanding of depression, its etiology, and classification is muddled and 
there’s still much confusion as to what depression is. Depression is a wide-reaching 
syndrome that is associated with many different mental health, physical health, and 
neurological disorders and not all manifestations of MDD respond to treatment the same, 
suggesting the possibility of differing etiologies. Further, depression ranges in severity 
and symptom presentation from psychotic to neurotic symptoms (Cole, McGuffin, & 
Farmer, 2008). The Diagnostic and Statistical Manual of Mental Disorders, 5th ed (2013) 
lists nine different symptoms of Major Depressive Disorder while only five need to be 
reported for a diagnosis of MDD. Considering these practices, two different people can 
be diagnosed with MDD and share only a single symptom. Further, there are vastly 
different pathways which a person can reach a depressed state (i.e. loss of a loved one, 
fired from job, genetic predisposition) as well as different trajectories of the disorder.  
 
Recovery Patterns 
Considering the heterogeneity and vast presentation of MDD, previous 
researchers have attempted to delineate specific MDD trajectory patterns. Hybels, Pieper, 
Blazer, and Steffens (2016) were able to identify four distinct patterns of recovery in 
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older adults diagnosed with MDD: a quick recovery class, a persistent moderate symptom 
class, a persistent high class, and a slow recovery class. It appeared that patients who 
were categorized as “quick recovery” had retained more of their instrumental activities of 
daily living (i.e. driving, cooking) and had higher levels of social support while patients 
who were classified as “persistent high symptom” had the highest levels of perceived 
stress and the least amount of social support. Further, patients who were classified as 
“slow recovery” had the earliest age of symptom onset. Results of this particular study 
imply that different recovery patterns and identifiable external and internal influences 
(i.e. social support, stress management) might offer insight into different subtypes of 
MDD.  
 
Subscales by Symptoms 
Other researchers have attempted to identify different subtypes of depression by 
performing factor analyses on depression indices. The Geriatric Depression Scale (GDS) 
is a commonly used measure of depression symptoms in older adults. Major strengths of 
the GDS include its high internal consistency (Cronbach’s alpha = .94) and simple “yes” 
and “no” format. In an attempt to identify possible subcategories of depression, Adams, 
Matto, and Sanders (2004) performed a confirmatory factor analysis of the 30-item GDS. 
They were able to identify five distinct subscales: Dysphoric Mood (Cronbach’s alpha = 
.80), Withdrawal-Apathy-Vigor (Cronbach’s alpha = .72), Hopelessness (Cronbach’s 
alpha = .65), Cognitive Impairment (Cronbach’s alpha = .52), and Anxiety (Cronbach’s 
alpha = .59). The Dysphoric Mood subscale describes depressed mood, sadness, 
emptiness, and an overall lack of satisfaction with life, which can be interpreted as the 
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“core” of a depression. The Hopelessness subscale encompassed symptoms of 
hopelessness, helplessness, and worthlessness, which the authors posit might be 
particularly useful when screening for suicidal ideation. The Withdrawal-Apathy-Vigor 
subscale incorporates items related to interests and activities and may represent behaviors 
and experiences that are influenced by age. The Anxiety subscale described obsessive 
ruminating, or worry, which captures the thinking and emotion problems that are 
common in MDD. Lastly, the Cognitive Impairment subscale address symptoms of 
confusion, concentration, and decision making. While these symptoms are common in 
MDD patients, they may also be indicative of other conditions such as dementia or a 
stroke. Implications of this study include the possibility of distinct subcategories of MDD 
and may improve the utility of the GDS for assessment and treatment purposes.  
 
Subscales and Cognitive Performance 
Prior research on depression subscales and cognitive performance has been 
relatively sparse. However, Turner, Capuano, Wilson, and Barnes (2015) identified the 
“Negative Affect” subscale on the 15-item GDS to be associated with a faster rate of 
decline in global cognition. This nine-item subscale makes up the bulk of the 15-item 
measure and, interestingly, encompasses items from several different subscales identified 
by Adams et al. (2004) on the 30-item GDS. It includes one item from the Cognitive 
Impairment subscale (“More problems with memory”), two items from the Dysphoric 
Mood subscale (“Often get bored”, “Most people are better off”), three items from the 
Withdrawal subscale (“Dropped activities”, “Prefer to stay home”, “Full of energy”), and 
three items from the Hopelessness subscale (“Feel helpless”, “Feel worthless”, “Situation 
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is hopeless”). Research with the Center for Epidemiological Studies-Depression (CES-D) 
measure—a 20-item measure of depression—identified the Depressed Affect subscale to 
associated with poorer performance on a task of non-verbal and abstract reasoning 
(Brailean et al., 2016). While the CES-D does not share the same wording as the GDS 
and GDS-15, several items within the Depressed Affect subscale are analogous to the 
Dysphoric Mood subscale on the GDS.  
 
Subsyndromal Symptomatic Depression 
Subsyndromal Symptomatic Depression (SSD), or subthreshold depression, can 
be defined as the presence of depressive symptoms which do not meet criteria for a 
diagnosis of depression as described in the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (Lyness, Chapman, McGriff, Drayer, & Duberstein, 2009). 
When assessed with a depression screener such as the Geriatric Depression Scale (GDS), 
SSD is typically defined as a score that is greater than zero and less than the clinical 
cutoff (Mackin et al., 2013; Royall, Palmer, Chiodo, & Polk, 2012). It is believed that 
roughly 15% of community-dwelling older adults and 50% of MCI patients qualify for 
SSD (Geda et al., 2008; Goldney, Fisher, Dal Grande, & Taylor, 2004). Research has 
indicated that SSD symptoms in community-dwelling adults may contribute to disability 
and functional impairments as well as put them at greater risk for developing MDD or 
dysthymia. (Chopra et al., 2005; Lyness et al., 2007). Further, due to the higher 
prevalence rates of SSD compared to MDD in the older adult population, SSD 
cumulatively accounts for greater functional morbidity than MDD (Lavretsky & Kumar, 
2002; Lyness et al., 2007). Unfortunately, due to the categorical nature of the Diagnostic 
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and Statistical Manual, those who do not meet the cutoff for a diagnosis of depression are 
often overlooked. While the relationship between MDD and MCI/Dementia has been 
well-established, the effects of SSD in community-dwelling older adults on cognitive 
performance—to our knowledge—has been less extensively examined and results have 
been mixed. In a study conducted by Mackin, Insel, Aisen, Geda, and Weiner (2012), a 
baseline diagnosis of SSD in MCI patients was not found to differentiate between AD 
converters and non-converters. Rather, it appeared that the stability and/or worsening of 
SSD symptoms over time was a better predictor of conversion. There is suggestion that 
symptoms of SSD are likely to persist as well as worsen, with SSD patients exhibiting a 
7-fold increased risk of developing MDD over the course of a year (Lyness et al., 2009). 
Further, other researchers have found significant differences in cognitive functioning 
between SSD individuals and non-depressed individuals in both cross-sectional and 
longitudinal design studies. For instance, SSD patients perform significantly worse than 
controls on tests of memory, language, and executive function at baseline (Dillon et al., 
2011; Gonzales et al., 2017). Overtime, subclinical mean GDS scores—which is 
congruent with the current definition of SSD—were found to predict cognitive decline 
over a three-year period in the domains of attention and executive functioning (Royall et 
al., 2012). There is also evidence to suggest that specific items on the GDS (memory 
problems, dropped activities and interests, preference for staying at home, and feelings of 
helplessness) may be especially relevant in predicting conversion to MCI/AD in SSD 
patients (Mackin et al., 2012). In a study that utilized autopsy and cognitive assessment 
data between 1991 and 2001 from the Honolulu-Asia Aging Study (HAAS), researchers 
found that SSD was significantly associated with subsequent cognitive decline, above and 
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beyond the effect of amyloid-related neuropathologies, neurofibrillary tangles, lewy 
bodies, and ischemic lesions (Royall & Palmer, 2013). Not only does it appear that SSD 
may be related to cognitive functioning, there is also evidence that indicates it 
compounds functional disability, which is a diagnostic symptom of dementia. In a 2-year 
longitudinal study, researchers found that within a sample of MCI participants, those who 
met criteria for SSD were 1.77 times more likely to have worse Functional Activity 
Questionnaire (FAQ) scores than those who did not meet criteria, suggesting that SSD 
exacerbates functional disability in individuals with MCI (Mackin et al., 2013), which 
corroborates previous findings (Porta-Etessam, Tobaruela-González, & Rabes-Berendes, 
2011).When examining neurometabolic differences, cognitively normal SSD patients 
exhibited decreased fluorodesoxyglucose (FDG) metabolism in mood-related brain 
regions, which may contribute to an increased risk for MCI/AD conversion (Brendel et 
al., 2016). SSD patients have also exhibited impaired functional deactivation in the 
posterior medial cortex (PMC) while similar impairments have been observed in AD 
patients (Woo, Prince, Petrella, Hellegers, & Doraiswamy, 2009).  
While there does appear to be evidence for a link between SSD and MCI/AD, the 
current literature is limited and a definitive agreement has yet to be reached. However, 
considering that SSD is associated with cognitive decline and MDD—which is 
considered a prodromal stage of dementia in late life—it is reasonable to assume that 
SSD in healthy older adults, particular those who have no prior history of depression, 
may mark the beginning stages of dementia (Barnes et al., 2012). If further evidence of 
significant differences in cognitive performance and disability are found in community-
dwelling older adults who exhibit SSD compared to those who do not, the implications 
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could be particularly salient for the treatment and course of MCI/Dementia. For instance, 
SSD is a treatable condition (Tadić et al., 2010). Studies examining the effectiveness of 
selective-serotonin reuptake inhibitors, problem-solving therapy, and exercise therapy for 
the treatment of minor depression showed promising results (Brenes et al., 2007; Oxman, 
Hegel, Hull, & Dietrich, 2008). Further, a study examining the effectiveness of problem-
solving therapy (PST) when treating individuals who presented with both Major 
Depression and MCI found that PST significantly reduced the burden of disability 
(Alexopoulos et al., 2011). If individuals who exhibit SSD are exposed to these early 
intervention techniques, it could potentially delay or even prevent the onset of 





THE PROPOSED STUDY 
 
Among those with measurable cognitive deficits, cognitive functioning can be 
perceived as a continuum, broadly encompassing age-associated memory impairment, 
mild cognitive impairment, and dementia. While it is not unusual to see slight decrements 
in certain cognitive processes with age, the risk for dementia increases overtime with 
prevalence rates of 15-20% after age 74 and 30-50% after age 85 (Schoenberg & Scott, 
2011). In its broadest definition, dementia is a clinical syndrome characterized by severe 
impairments in one or more cognitive domains with accompanying functional 
impairments. There are several different types of dementias which are classified by 
etiology and presenting symptoms, the most common of which is Alzheimer’s Disease 
(AD).  
Neuropsychological testing is useful for identifying those most at risk for 
cognitive impairment (Jack et al., 1999; Mosconi et al., 2004; Shaw et al., 2009; Tabert et 
al., 2006). Further, several other risk factors for cognitive impairment have been 
identified, including: age, family history, certain genetic factors, poor cardiovascular 
health, previous traumatic brain injuries, and a history of neuropsychiatric illness 
(Schoenberg & Scott, 2011). Major depressive disorder (MDD), specifically, has been 
pinpointed as a particularly salient neuropsychiatric risk factor. Examination of the 
biological relationship between MDD and dementia—specifically AD—has found shared 
underlying pathology in the CNS and similar disturbances in the hypothalamic-pituitary-
adrenal axis (Huang et al., 2009; Zweig et al., 1988). The current consensus is that MDD 
represents an independent risk factor for AD early in life while late-life MDD can be 
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construed as a prodromal stage of the disease (Barnes et al., 2012). Symptoms of 
depression also appear to expedite dementia decline and exacerbate functional disability 
(Modrego & Ferrández, 2004; Starkstein et al., 2005).  
While the relationship between MDD and cognitive impairment has been well-
established, less research has examined the effects of minor depression, or subsyndromal 
symptomatic depression (SSD), on cognitive ability in otherwise healthy, community-
dwelling older adults. The current proposed study intends to examine the relationship 
between SSD and cognitive ability in a sample of healthy, non-demented older adults. If a 
relationship between SSD and cognitive dysfunction is established, future research can 
examine SSD’s effect on conversion rates to MCI/dementia as well as the efficacy of 
SSD treatment as preventative care. Implications include the identification of a possible 
early clinical marker for AD as a point of intervention. Further, MDD is a heterogeneous 
disorder with differing catalysts, symptoms, trajectories, and outcomes (Diagnostic and 
statistical manual of mental disorders: DSM-5™., 5th ed, 2013; Hybels et al., 2016). To 
our knowledge, the research is limited on whether specific clusters of depression 
symptoms are associated with an increased risk for developing MCI/dementia and has not 
been explored with the 30-item GDS. The proposed study will also attempt to delineate 
whether specific clusters of depression symptoms are disproportionally associated with 
cognitive impairment. If a pattern is identified, treatments specifically designed to target 






Aim 1. Determine whether Subsyndromal Symptomatic Depression  
is Related to Cognitive Deficits. 
Hypothesis: We predict that Subsyndromal Symptomatic Depression (SSD) will 
predict cognitive functioning, such that participants who exhibit symptoms of SSD will 
perform worse on measures of neuropsychological functioning than participants who do 
not exhibit SSD. 
Null Hypothesis: There will be no significant differences on measures of 
neuropsychological functioning between participants who exhibit SSD and those who do 
not. 
 
Aim 2. Determine Whether Specific Symptoms of Depression 
 are Specifically Tied to Cognitive Deficits. 
Hypothesis: We predict that certain clusters of depression symptoms will be 
disproportionally associated with deficits in cognitive functioning.   
Null Hypothesis: There will be no significant pattern of depression symptoms 
associated with deficits in cognitive functioning.   
 
Experimental Plan/Study Design 
 
Subjects 
 One hundred and six participants, 65 and older were recruited as part of the 
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Adventist Health Study-2 Cognition and Neuroimaging Substudy (AHS-2 CAN; 
accessible population). Recruitment began in June 2016 and continued through August 
2018. The study was designed to examine relationships between cognitive function and 
dietary patterns among Seventh-Day Adventist church members over the age of 65. They 
were informed of the purpose of the study. Exclusion criteria included a diagnosis of 
dementia, a history of significant neurologic disease or insult, substance abuse or 
dependence within the last 2 years, a medical illness that could affect cognition, and a 
GDS score greater than 9. Results of the study will, ideally, be generalizable to healthy, 
older Americans with non-clinical depression (theoretical population).  
 
Methods 
 After providing informed consent, participants underwent a 2-hour 
comprehensive neuropsychological battery in Loma Linda University’s 
Neuropsychological Assessment and Neuroimaging Lab. The battery measured multiple 
domains of functioning, including: Premorbid Verbal Intelligence, Attention/Processing 
Speed, Language, Visuospatial ability, Verbal Memory, Non-verbal Memory, and 
Executive Functioning. Presence of depressive symptoms was assessed using the 
Geriatric Depression Scale (GDS). Participants’ background and demographic 
information was also collected, including: age, gender, marital status, ethnicity, 
handedness, years of education, vision and hearing deficits, psychiatric history, 
medication use, social history, and family history of neurological/psychiatric problems. 
The battery was administered by a trained lab assistant using a standardized procedure. 
Total time to complete an assessment took approximately 2 hours. The full 
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neuropsychological battery can be found in Appendix B. All key personnel have 




Mini-Mental State Exam (MMSE) 
The Mini-Mental State Exam is a 30-point screening tool used to measure global 
cognitive functioning and is most commonly used to screen for dementia. Administration 
takes 5 to 10 minutes and examines orientation, registration, attention and calculation, 
recall, language, and visual construction (Folstein, Folstein, & McHugh, 1975).  
 
Montreal Cognitive Assessment (MOCA) 
The Montreal Cognitive Assessment is a 30-point screening measure used to 
assess for mild cognitive impairment. Administration takes 5 to 10 minutes and examines 
visuospatial/executive ability, naming, memory, attention, language, abstraction, delayed 
recall, and orientation (Nasreddine et al., 2005). 
 
Rey Auditory Verbal Learning Test (RAVLT) 
 The Rey Auditory Verbal Learning Test is a measure of short-term auditory-
verbal memory, rate of learning, learning strategies, retroactive and proactive 
interference, retention, confabulation, and retrieval. Initial administration takes 15 




Rey Complex Figure Test (RCFT) 
The Rey Complex Figure Test is a measure of visuospatial abilities, visual 
memory, and planning. The participant is asked to reproduce a complex figure, first by 
copying and later from memory following a three minute delay (André Rey & Osterrieth, 
1941) 
 
Wechsler Adult Intelligence Scale-IV Coding (CD) 
Coding is subtest of the WAIS-IV and measures psychomotor and processing 




Stroop Word Trials and Color Trials are measures of verbal information 
processing speed while Color/Word Trials is an executive measure of response inhibition 
(Golden, Freshwater, & Golden, 2002). 
 
Wechsler Adult Intelligence Scale-IV Digit Span (DS) 
Digit Span is a subtest of the WAIS-IV and measures working memory, attention, 
encoding, and auditory processing. The participant is required to recall a series of 
numbers in order (Wechsler, 2008).  
 
Trail Making Test Parts A & B (TMT A&B) 
Trails A measures processing speed, psychomotor speed, and visual motor 
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tracking while Trails B measures set-shifting and cognitive flexibility, which are 
executive skills. Trails A consists of 25 circles numbered 1-25 distributed over a sheet a 
paper which the participant must connect in consecutive order. Trails B consists of 25 
circles—numbers and letters—which the participant must alternate between in 
consecutive order (Reitan & Wolfson, 1986).  
 
Wechsler Memory Scale-IV Logical Memory (LM) 
Logical Memory (LM) is a subtest of the WMS-IV. The participant is presented 
with two short stories which they must recall immediately (LMI) and then after a 30-
minute delay (LMII). This subtest measures immediate, delayed, and recognition memory 
of contextualized verbal information ("Wechsler Memory Scale--Fourth Edition," 2009).  
 
Boston Naming Test (BNT) 
The Boston Naming Test is a 60-item measure of confrontational object naming. 
The participant is presented with a series of images which they must name (Kaplan, 
Goodglass, & Weintraub, 2001).  
 
Controlled Oral Word Association Test (COWAT) 
The Controlled Oral Word Association Test is a verbal fluency test that measures 
spontaneous production of words either beginning with a designated letter (FAS) or 
belonging to a category (Animals). FAS, specifically, measures phonemic verbal fluency 




Geriatric Depression Scale Long Form (GDS) 
The Geriatric Depression Scale is a 30-item questionnaire used to identify 
depression in the elderly. Items reflect depressive symptoms and are answered in a “yes” 
or “no” format (Yesavage et al., 1983).  
 
Clinical History Form 
The Clinical History Form is used to obtain demographic and other background 
information from the participant. Information collected includes: age, gender, marital 
status, ethnicity, handedness, years of education, vision and hearing deficits, psychiatric 
history, medication use, and family history of neurological/psychiatric problems 
 
Operational Definitions 
I. Independent Variables  
a. Depression Severity  
i. Non-depressed (GDS = 0) 
ii. Subsyndromal Symptomatic Depression (GDS = 1-9)  
b. Depression Subscales  
i. Dysphoric Mood (GDS items 16, 9, 3, 1, 23, 7, 4, 25, 15) 
ii. Withdrawal-Apathy-Vigor (GDS items 12, 28, 2, 19, 20, 21) 
iii. Anxiety (GDS items 8, 13, 6, 18) 
iv. Cognitive (GDS items 26, 30, 29) 
v. Hopelessness (GDS items 22, 10, 17, 5) 
II. Dependent Variables  
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a. Individual Neuropsychological Tests 
i. MMSE 
ii. MoCA 
iii. WAIS-IV DS, CD 
iv. Stroop A, B, & C 
v. Trails A & B 
vi. BNT 
vii. COWAT (FAS and Animals) 
viii. RCFT Copy and Immediate Recall  




 SPSS was used to analyze the data and an alpha of 0.05 was used for all statistical 
significant tests. Independent sample t-tests were conducted to determine whether 
significant differences in cognitive functioning can be observed been participants who 
endorse SSD symptoms of depression and those who do not endorse symptoms of 
depression. The independent variable was depression severity (Subsyndromal 
Symptomatic Depression and Non-depressed). The dependent variables were the 
neuropsychological measures included in the battery: WAIS-IV DS, WAIS-IV Coding, 
Stroop A & B & C, Trails A & B, BNT, FAS, Animals, Rey-O Copy and Immediate 





SPSS was used to analyze the data and an alpha of 0.05 was used for all statistical 
significant tests. A series of multiple linear regressions were conducted to evaluate which 
GDS subscales were the most important predictors of cognitive functioning. For each 
multiple regression, the independent variables were the GDS subscales: Dysphoric Mood, 
Withdrawal-Apathy-Vigor, Anxiety, Cognitive Impairment, and Hopelessness. Age, 
Education, and Gender were included in each model during Step 1 as controls. During 
Step 2, Hopelessness, Cognitive Impairment, Dysphoric Mood, Anxiety, and Withdrawal 
were included in the model.  For the first analysis, the dependent variable was MoCA 
scores (Table 5). For the second analysis, the dependent variable was RAVLT immediate 
memory scores while for the third and fourth analyses the dependent variable was 
RAVLT short delay and RAVLT long delay, respectively. It should be noted that our data 
violated the assumption of normality. A square root transformation was performed to 
address this violation, however, the difference in results between the transformed and 
non-transformed data was negligible. While we will report the results for both our non-
transformed (Table 5) and transformed data (Table 6), for interpretability’s sake, we 







Aim 1: Determine Whether Subsyndromal Symptomatic Depression  
is Related to Cognitive Deficits. 
Of the 106 participants, 84 were in the SSD group and 22 were in the non-SSD 
group. The two groups were similar in age, education, race, MMSE, and MoCA scores 
(Table 1). Independent samples t-tests were conducted to evaluate whether there were 
significant differences in cognitive performance between SSD and non-SSD participants. 
Cognitive test scores were reported as age-adjusted z-scores. A Bonferroni type 
adjustment was run to correct for multiple comparisons. On the RAVLT, there was a 
significant difference in the immediate recall over five learning trials (List A, Trials 1-5) 
between the SSD group (M=-0.14, SD=1.16) and the non-SSD group (M=0.89, SD=0.96, 
t(104)=3.84, p < 0.001). However, there were no significant differences between the two 
groups on the RAVLT after a delay nor were any significant differences observed on the 
WMS-IV LM—another measure of immediate (LM I) and delayed (LM II) memory. No 
other significant differences on any other measure of cognitive functioning were 


















SSD (n = 84) 
Mean (SD) 
 




      
Age, Years  74.81 (8.28)  72.68 (7.19)  
Education, Years  16.69 (2.56)  17.32 (2.61)  
Gender (M/F)  36M/44F  10M/12F  
Race, % Caucasian  84.80%  68.20%  
MMSE  29.15 (1.14)  29.09 (1.07)  
MMSE % 
Impaired 
 0  0  
MoCA  25.50 (3.14)  25.27 (2.82)  
MoCA % 
Impaired 











Table 2. Neuropsychological Test Scores reported as age-adjusted z-scores for 




SSD (n = 84) 
Mean (SD) 
 
Non-SSD (n = 
22) 
Mean (SD) 
 P values 
       
RAVLT Immediate  -0.14*** 
(1.16) 
 0.89*** (0.96)  p = 0.001 
RAVLT SD  -0.20 (1.18)  0.37 (0.96)  p = 0.056 
RAVLT LD  -0.05 (1.39)  0.43 (1.17)  p = 0.167 
WMS-IV LMI  0.13 (0.97)  0.43 (0.71)  p = 0.291 
WMS-IV LMII  0.14 (1.05)  0.41 (0.68)  p = 0.225 
WAIS-IV DSF  -0.10 (0.83)  0.00 (1.00)  p = 0.954 
WAIS-IV DSB  0.19 (0.93)  0.32 (1.04)  p = 0.587 
WAIS-IV DSS  0.27 (0.89)  0.27 (0.66)  p = 0.998 
WAIS-IV CD  0.10 (3.76)  0.50 (0.68)  p = 0.626 
Stroop A  -0.99 (0.96)  -0.91 (0.88)  p = 0.984 
Stroop B  -1.17 (0.91)  -1.09 (0.73)  p = 0.904 
Stroop C  -0.54 (0.83)  -0.61 (0.84)  p = 0.614 
Trails A  0.48 (1.09)  0.63 (0.85)  p = 0.728 
Trails B  -0.51 (2.54)  -0.14 (1.15)  p = 0.541 
BNT  0.17 (1.48)  0.61 (0.81)  p = 0.194 
FAS  -0.35 (0.88)  -0.08 (0.69)  p = 0.148 
Animals  0.10 (0.95)  0.23 (1.10)  p = 0.987 
Rey-O Copy  -0.69 (1.38)  -0.48 (1.17)  p = 0.586 
Rey-O Delay  0.40 (1.43)  0.42 (1.71)  p = 0.992 
MoCA  25.44 (3.09)  25.27 (2.82)  p = 0.689 
MMSE  29.14 (1.12)  29.09 (1.07)  p = 0.726 




Aim 2. Determine Whether Specific Symptoms of Depression 
Are Specifically Tied to Cognitive Deficits. 
Within our SSD group (N=84), Cognitive Impairment symptoms were the most 
commonly endorsed items, with 73.80 percent (N =62) of participants endorsing at least 
one item. Withdrawal-Apathy-Vigor symptoms were the second most commonly 
endorsed items, with 69.05 percent (N =58) of participants endorsing at least one item. 
Anxiety and Dysphoric Mood symptoms followed, with 19.05 percent (N=16) and 15.48 
percent (N=13) of participants endorsing at least one item, respectively. Lastly, 
Hopelessness symptoms were the least endorsed items, with 7.14 percent (N=6) of the 
sample endorsing at least one item (Table 3).  
 
Table 3. Summary of GDS and GDS Subscale Endorsement 
Subscale (Total Possible Points)  N (%)  M (SD) 
GDS (30)  84 (100)  3.65 (2.75) 
Cognitive (3)  62 (73.80)  1.37 (0.61) 
Withdrawal (5)  58 (69.05)  2.08 (1.23) 
Anxiety (3)  16 (19.05)  1.31 (0.70) 
Dysphoric (4)  13 (15.48)  1.69 (1.11) 
Hopelessness (2)  6 (7.14)  1.17 (0.41) 
 
 
A summary of Pearson’s correlation coefficients for the five GDS subscales can 
be found in Table 4. Controlling for age, education, and gender, a multiple linear 
regression was conducted to evaluate which GDS subscales were the most important 
predictors of MoCA scores. When examining the non-transformed data, the final 
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regression model accounted for a significant proportion of the variance in MoCA scores, 
such that the optimal linear combination of all five depression subscales, age, education, 
and gender accounted for 30% of the variance in MoCA scores, R2adj = .30, F(8,74) = 
5.34, p < .01. Of the five subscales included in the model, Hopelessness, Dysphoric 
Mood, and Cognitive Impairment were significant predictors above and beyond the 
effects of age, education, and gender. Of the five subscales, Hopelessness was the most 
important predictor of MoCA scores, which accounted for 11.16% of the variance. As 
Hopelessness increased by one unit, MoCA scores decreased by .293 units, CI [-4.72, -
0.99], p < .01. Dysphoric Mood accounted for 7.02% of the variance in MoCA scores. As 
Dysphoric Mood increased by one unit, MoCA scores decreased by .248 units, CI [-1.90, 
-0.16], p < .05. Cognitive Impairment accounted for 5.66% of the variance in MoCA 
scores. As Cognitive Impairment increased by one unit, MoCA scores increased by .404 
units, CI [0.05, 1.66], p < .05. Anxiety and Withdrawal-Apathy-Vigor were not 
significant predictors (Table 5).  
 
Table 4. Pearson’s Correlation Coefficients for GDS Subscales 
  Dysphoric Withdrawal Anxiety Cognitive Hopelessness 
Dysphoric  1     
Withdrawal  0.43** 1    
Anxiety  0.09 0.05 1   
Cognitive  0.09 0.23* 0.19 1  
Hopelessness  0.11 0.05 -0.05 -0.01 1 
 






Table 5. Summary of Hierarchical Regression Analysis with non-transformed MoCA  
 scores as the Dependent Variable 
 
Note. B = non-standardized coefficients; SE = standard error;  = standardized 
coefficients;  





When examining the transformed data, the final regression model accounted for a 
significant proportion of the variance of the square root of MoCA scores, such that the 
optimal linear combination of all five depression subscales, age, education, and gender 
accounted for 29% of the variance in the square root of MoCA scores, R2adj = .29, 
F(8,78) = 5.02, p < .01. Of the five subscales included in the model, Hopelessness, 
Dysphoric Mood, and Cognitive Impairment were significant predictors above and 
beyond the effects of age, education, and gender. Of the five subscales, Dysphoric Mood 
Depression Subscale  B SE B  R R² R² 
Step 1     0.42 0.18 0.18*** 
Age  -0.11** 0.04 -0.30    
Education  0.28* 0.11 -0.24    
Gender  0.62* 0.30 0.20    
        
Step 3     0.59 0.34 0.16*** 
Age  -0.09** 0.03 -0.24    
Education  0.27* 0.11 0.23    
Gender  0.31 0.28 0.10    
Hopelessness  -2.90** 0.93 -0.28    
Dysphoric Mood  -1.02* 0.43 -0.23    
Cognitive Impairment  0.83* 0.38 0.22    
Anxiety  -0.46 0.49 -0.09    
Withdrawal  0.11 0.23 0.05    
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was the most important predictor of the square root of MoCA scores, which accounted 
for 8.88% of the variance. As Dysphoric Mood increased by one unit, the square root of 
MoCA scores decreased by .269 units, CI [-0.57, -0.08], p < .05. Hopelessness accounted 
for 7.24% of the variance in the square root of MoCA scores. As Hopelessness increased 
by one unit, the square root of MoCA scores decreased by .231 units, CI [-1.00, -0.08], p 
< .05. Cognitive Impairment accounted for 5.95% of the variance in the square root of 
MoCA scores. As Cognitive Impairment increased by one unit, the square root MoCA 
scores increased by .228 units, CI [0.01, 0.40], p < .05. Anxiety and Withdrawal-Apathy-
Vigor were not significant predictors (Table 6). When RAVLT immediate memory, 
RAVLT short delay, and RAVLT long delay were included as the dependent variable and 




































Table 6. Summary of Hierarchical Regression Analysis with transformed MoCA scores 
as the Dependent Variable 
Depression Subscale   B SE B  R R² R² 
Step 1      0.45 0.20 0.20*** 
Age  -0.03*** 0.01 -0.35    
Education   0.08* 0.03 -0.28    
Gender   0.14 0.08 0.19    
         
Step 3      0.60 0.36 0.16*** 
Age  -0.02** 0.01 -0.27    
Education  0.08* 0.03 0.27    
Gender  0.06 0.08 0.08    
Hopelessness   -0.5* 0.23 -0.23    
Dysphoric Mood  -0.33* 0.12 -0.27    
Cognitive Impairment   0.21* 0.10 0.23    
Anxiety   -0.08 0.14 -0.06    
Withdrawal  0.04 0.06 0.07    
 
Note. B = non-standardized coefficients; SE = standard error;  = standardized 
coefficients;  











Our study provides two main contributions: (1) we identified significant 
differences in verbal learning and memory between SSD and non-SSD participants; and 
(2) we identified specific clusters of depression symptoms which are more closely tied to 
cognitive deficits.  
 
Aim 1: Determine Whether Subsyndromal Symptomatic Depression 
is Related to Cognitive Deficits. 
We intended to examine the relationship between SSD and cognitive ability in a 
sample of community-dwelling, healthy, older adults to determine whether significant 
differences in cognitive functioning could be observed between individuals who 
exhibited subthreshold depression symptoms and those who did not endorse symptoms of 
depression. After conducting a series of independent samples t-tests, we demonstrated 
that participants who endorsed subthreshold depression symptoms performed 
significantly worse on certain measures of cognitive functioning than participants who 
denied experiencing symptoms of depression. Specifically, we found differences in 
performance on the Rey Auditory Verbal Learning Test (RAVLT), which is a measure of 
verbal learning and memory (A. Rey, 1958). Briefly, the RAVLT consists of five 
presentations—or learning trials—of a 15-word list (List A, Trials 1-5) which is followed 
by an intervening interference list (List B) and then a subsequent free recall trial of the 
original list (List A, Trial 6). A delayed free recall trial (List A, Trial 7) is administered 
20-30 minutes after the initial administration. Participants who endorsed subthreshold 
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depression symptoms performed significantly worse than participants who did not 
endorse depression symptoms on the five learning trials (List A, Trials 1-5). This 
corroborates our hypothesis that, even at the subthreshold level, depression symptoms 
may have a significant impact on cognitive functioning. A possible explanation for our 
SSD participants’ inferior performance on the initial learning trials is that this task puts a 
greater load on attention and concentration capabilities. During the initial learning trials, 
the participant is instructed to retain and memorize a list of words for which they will 
need to recall at a later time. Potentially, our participants who endorsed subthreshold 
depression symptoms had more difficulty encoding new information than our participants 
who did not endorse depression symptoms, hinting at the possibility of issues related to 
attention.  
Attention, in its most basic form, can be described as the ability to recognize and 
respond to changes in the environment. In addition to orienting us, attention plays a 
crucial role in memory as it is essential in encoding information into new memories 
(Schoenberg & Scott, 2011). While several regions of the brain are involved in different 
aspects of attention, it is within the frontal lobes that the bulk of our attentional processes 
are located. The prefrontal cortex (PFC)—which is responsible for voluntary initiation of 
attention—seems to be particularly important during the acquisition of new information. 
Balthazar, Yasuda, Cendes, and Damasceno (2010) found the learning phase of the 
RAVLT to be strongly related to the medial prefrontal cortex (MPC) while the medial 
temporal lobes, specifically the hippocampus, are involved in the formation and storage 
of memories. While the MPC seems to be associated with the selection, manipulation, 
and maintenance of new information, it appears that the lateral prefrontal cortex (LPC) is 
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responsible for memory retrieval (Petrides, 2002).  If we are to assume our SSD 
participants had underperforming medial prefrontal cortices with intact medial temporal 
lobes and lateral prefrontal cortices, this distinction—in part—may explain why we 
observed significant differences during the RAVLT learning trials (List A, Trials 1-5) but 
not during the delayed recall trials (List A, Trial 6 & 7).  
To further clarify why our SSD participants may have had lower scores on tests 
associated with medial prefrontal cortices, brain-imaging studies of depressed patients 
have found consistent evidence of decreased neuronal volume of the PFC (Duman & 
Aghajanian, 2012). This decrease in size may be the result, in part, of acute and chronic 
stress associated with depression which has been shown to cause neuronal atrophy of the 
medial prefrontal cortex (Cowen, 2010; McEwen, Eiland, Hunter, & Miller, 2012). In 
fact, atrophy of the PFC pyramidal neurons can be observed in as little as one week after 
chronic stress exposure (Liu & Aghajanian, 2008). Further, PFC atrophy in healthy, 
undemented older adults was found to be a superior predictor of dementia conversion 
over a nine-year period than medial temporal lobe atrophy (Burgmans et al., 2009). 
Taking this into consideration, it is possible that even at the subthreshold level, the 
presence of depression symptoms has a significant impact on brain integrity and may 
increase risk of dementia conversion.  
While the literature is limited, prior research has observed deficits on tests of 
memory, language, and executive functioning for SSD participants with cognitive 
complaints when compared with controls (Dillon et al., 2011; Gonzales et al., 2017).  Our 
results are partially consistent with these findings. Specifically, Gonzales et al. (2017) 
found significant differences at baseline on the RAVLT immediate recall between SSD 
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and non-SSD MCI participants. Further, Dillon et al. (2011) identified SSD participants 
with deficits on Logical Memory I (LMI)—a subscale of Wechsler Memory Scale-IV—
which, like the RAVLT, is a measure of immediate memory. However, we did not 
observe differences in delayed memory, language, or other measures of executive 
functioning. These differences may be attributed to several factors. For instance, prior 
research has utilized participants with cognitive complaints and those already diagnosed 
with MCI while our participants were healthy individuals with no prior diagnosed 
cognitive disorders. Further, there appears to be slight differences in how we defined 
“subsyndromal depression”. While Dillon et al. (2011) utilized the Beck Depression 
Inventory and excluded participants who scored below eight, we used the Geriatric 
Depression Scale and defined SSD as those who endorsed between one and nine 
symptoms which is below the clinical cutoff on the GDS and consistent with several 
previous studies (Gonzales et al., 2017; Mackin et al., 2012).  
While previous literature has provided evidence for cognitive deficits in SSD 
participants with cognitive concerns, our results are novel in that we demonstrated that 
cognitive deficits can be observed in healthy, older adults who endorse at least one 
symptom of depression. Depression—specifically Major Depressive Disorder—has long 
been linked with cognitive impairment. Currently, there is evidence to suggest that MDD 
represents an independent risk factor for Alzheimer’s Disease in early life while it may 
represent a prodromal stage of the disease in late life (Barnes et al., 2012; Ownby et al., 
2006). The results of our study suggest that, even at the subthreshold level, depression 
may be a viable clinical marker for cognitive impairment. Implications of these results 
could mean utilization of the GDS—or other depression measures—as screeners for 
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individuals at risk for MCI/Dementia which may allow for early intervention. SSD 
treatment, in particular, is noteworthy as research has shown that the disorder is 
responsive to low-dose selective-serotonin reuptake inhibitors, problem-solving therapy, 
and exercise therapy (Brenes et al., 2007; Oxman et al., 2008; Tadić et al., 2010). Further, 
it is believed that roughly 15% of community-dwelling older adults and 50% of MCI 
patients qualify for SSD and that these individuals are at a 7-fold increased risk of 
developing MDD, highlighting the urgency and need for treatment (Geda et al., 2008; 
Goldney et al., 2004; Lyness et al., 2009). Early detection and treatment of SSD could 
potentially prevent worsening of depression symptoms as well as delay—or even curb—
the manifestation of MCI/Dementia in later life. 
 
Aim 2: Determine Whether Specific Symptoms of Depression  
are Specifically Tied to Cognitive Deficits. 
In addition to identifying differences in cognitive functioning between SSD and 
non-SSD participants, we aimed to determine whether specific symptoms of depression 
are more closely tied to cognitive dysfunction. We utilized the work of Adams et al. 
(2004) to categorize depression symptoms on the GDS into five distinct subscales: 
Dysphoric Mood, Withdrawal-Apathy-Vigor, Hopelessness, Cognitive Impairment, and 
Anxiety. It should be noted that our data violated the assumption of normality, which was 
to be expected, considering our population of interest were community-dwelling, healthy, 
older adults and high endorsement of depression symptoms was not anticipated. A square 
root transformation was performed to address this violation, however, the difference in 
results between the transformed and non-transformed data was negligible. For 
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interpretability’s sake, we argue that interpretation of the data in its original form, with 
caution, is the best mode of action. However, after conducting a hierarchical linear 
regression, we demonstrated that depression symptoms related to Hopelessness, 
Dysphoric Mood, and Cognitive Impairment were significant predictors of MoCA 
scores—a commonly used measure of global cognitive functioning—above and beyond 
the effects of age, education, and gender. Specifically, we found that endorsement of 
symptoms related to Hopelessness and Dysphoric Mood were related to a decrease in 
cognitive performance while endorsement of Cognitive Impairment symptoms, 
paradoxically, were associated with improved cognitive functioning.  
While depression has previously been linked to reduced cognitive functioning, 
our understanding of the specific symptoms related to these deficits are limited. 
Depression is heterogeneous in presentation, encompassing a wide array of symptoms 
including depressed/dysphoric mood, cognitive symptoms, somatic symptoms, and 
reduction in positive affect (Baune, Suslow, Arolt, & Berger, 2007). In fact, previous 
research has identified several distinct factors—or subscales—within depression 
screeners such as the GDS and CES-D (Adams et al., 2004; Brailean et al., 2016). The 
results of our study suggest that depression symptoms on the GDS related to 
Hopelessness and Dysphoric Mood may be predominately responsible for deficits in 
global cognitive functioning. The Hopelessness cluster consists of four items that deal 
with hopelessness, helplessness, and worthlessness. These feelings, in particular, have 
been shown to be predictive of suicidal ideation and behavior (Brown, Beck, Steer, & 
Grisham, 2000; Jeon et al., 2014; Lester & Walker, 2007). Taking this into consideration, 
the Hopelessness cluster may be important not only for screening cognitive dysfunction 
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but also assessing suicidal ideation or intent. The Dysphoric Mood cluster consists of 
nine items that detail depressed mood, emptiness, and a lack of happiness and satisfaction 
with life and is described by Adams et al. (2004) to be the “core of depressed mood” on 
the GDS. Our results are similar to previous research which identified the “Negative 
Affect” subscale on the 15-item GDS as predictive of a faster rate of decline in global 
cognition (Turner et al., 2015). The “Negative Affect” subscale shares many similarities 
with both our Hopelessness and Dysphoric Mood subscales—including items 4, 10, 17, 
22, and 23—and can be considered the “core of depressed mood” on the 15-item GDS. 
Further, our Dysphoric Mood subscale shares many similarities with the Depressed 
Affect factor on the CES-D which has previously been linked to poor performance on a 
measure of non-verbal and abstract reasoning (Brailean et al., 2016).   
While the results of our study suggest that Hopelessness and Dysphoric Mood 
clusters are related to reduced cognitive performance, endorsement of symptoms found 
within the Cognitive Impairment subscale were, oddly, associated with improved 
cognition. On the GDS, this cluster includes items that encompass confusion, difficulties 
with decision making, and reduced concentration. Though the results of our study appear 
counterintuitive, previous research has indicated that cognitive concerns are more closely 
linked to symptoms of depression and anxiety rather than objective cognitive decline 
(Cargin, Collie, Masters, & Maruff, 2008). In fact, patients diagnosed with MDD tend to 
underestimate their cognitive functioning while individuals with objective cognitive 
decline appear to have impaired awareness of their deficits and tend to overestimate their 




Symptoms on the GDS related to Cognitive Impairment were the most commonly 
endorsed items, with 74 percent of our sample endorsing at least one item within this 
cluster. This high level of endorsement is consistent with previous research which has 
found endorsement upwards of 75 percent in healthy, older adults (Ginó et al., 2010; João 
et al., 2016). With this in mind, it appears that complaints of impaired or declining 
memory are often reported despite any objective cognitive deficits. Further, there is 
evidence that suggests brief dementia screening tests—such as the MoCA—are not 
sensitive enough to detect impairment in cognitive functioning at the early stages of 
dementia in highly educated older adults (Geerlings, Jonker, Bouter, Adèr, & Schmand, 
1999). Considering 69 percent of our sample had at least a Bachelor’s degree, with 25 
percent having obtained a doctorate, it is possible that any subjective cognitive 
complaints these individuals had were not detected on the MoCA. On the flipside, it is 
feasible to assume that our participants with impaired awareness of their cognitive 
deficits were less likely to endorse symptoms related to Cognitive Impairment. Taken 
together, this may explain why we observed improved functioning in our participants 
who endorsed symptoms within the Cognitive Impairment cluster.  
The results of our study suggest that depression symptoms related to 
Hopelessness and Dysphoric Mood may be predictive of reduced cognitive functioning. 
While treating depression as a whole is certainly the goal, it may be efficacious to target 
symptoms related to Hopelessness and Dysphoric Mood in order to alleviate any 
cognitive dysfunction. Clinicians have long postulated that depression is not a monolithic 
disorder but rather a group of disorders which are heterogeneous in onset, symptoms, 
course, and treatment. While Dysphoric Mood symptoms—which includes feelings of 
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sadness, emptiness, and lack of satisfaction with life—may be described as the “core of 
depression”, hopelessness has been identified as a possible subtype of depression which 
is aptly named hopelessness depression (Abramson, Metalsky, & Alloy, 1989). Research 
exploring the efficacy of treatment interventions—both psychotherapeutic and 
psychopharmacological—have shown promising results for both classifications of 
depression, suggesting interventions can be specifically tailored to address any cognitive 
concerns related to depression by way of Dysphoric Mood and Hopelessness symptoms 
(Driessen & Hollon, 2010; Handley et al., 2013). 
In light of our findings in Aim 1—that there are significance differences in 
RAVLT immediate recall scores between our SSD and non-SSD participants—we also 
examined whether our depression subscales predicted RAVLT scores. We ran three 
separate models with RAVLT immediate recall, RAVLT short delay, and RAVLT long 
delay as our dependent variables. Unfortunately, none of these additional models were 
significant. Due to our findings in Aim 1, we had anticipated significance when RAVLT 
immediate recall was included in our model. Seeing as we did not observe significant 
differences among our SSD group, it is possible that the effect of depression on 
immediate verbal memory is only observed between depressed and non-depressed 
groups. This is to say that within a depressed group, the specific symptoms of depression 
have less of an effect on immediate verbal memory. Another possible explanation for our 
insignificant results is insufficient power. To further clarify, a multiple linear regression 
analysis—our analysis of choice for Aim 2—requires more power than the t-test we used 
in Aim 1. This suggests that our sample size, while sufficient for Aim 1, may not have 
been large enough to detect significance in Aim 2 when RAVLT immediate recall was 
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included in the model. It should be noted, however, that when RAVLT immediate recall 
was included, the GDS subscale Hopelessness was significant despite the overall model 
not being statistically significant. This is particularly noteworthy as Hopelessness was 
one of most significant predictors of global cognitive functioning when MoCA scores 
were used in our model. While we are unable to conclude that Hopelessness predicts 
RAVLT immediate recall scores, future studies with larger sample sizes may be able to 
further clarify the relationship between GDS subscales and RAVLT scores.  
 
Limitations and Future Directions 
Our study has several limitations. While there is evidence that suggests depression 
is a prodromal stage of dementia (Anstey et al., 2007), research has found that depressed 
patients exhibit greater cognitive impairment than healthy controls (Lim et al., 2013). 
While we were able to identify deficits in cognitive functioning amongst our SSD 
participants, whether these deficits are indicative of the prodromal stage of dementia or 
independently caused by depression is difficult to delineate with the cross-sectional 
design we employed. Future research should utilize a longitudinal study design that 
examines conversion rates of SSD to MCI/dementia to conclude that SSD represents a 
clinical marker of dementia. However, we have laid the necessary groundwork for future 
research to further examine this relationship.  
A second limitation of our study is the non-normality of our data regarding 
symptom depression endorsement. As we utilized healthy, community-dwelling, older 
adults as our population of interest, we did not—nor did we expect to—observe high 
endorsement of depression symptoms on the GDS. However, when a square root 
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transformation was performed to address this violation, the difference in results between 
the transformed and non-transformed data was negligible. For interpretability’s sake, we 
argue that interpretation of the data in its original form, with caution, is the best mode of 
action. With that said, future research should utilize a population with a more robust 
depression symptom endorsement in order to better elucidate the relationship depression 
subscales and cognitive functioning.  
 A third limitation of the current study includes the degree to which the results can 
be generalized to the greater population. The sample of interest consists solely of healthy, 
Seventh-day Adventists living in Southern California. There is evidence to suggest that 
religiosity protects against cardiovascular disease, which is a risk factor for dementia 
(Powell, Shahabi, & Thoresen, 2003). Further, the population of interest 
disproportionally resides in Loma Linda, California, which has been identified as a “Blue 
Zone”—or a region where people demonstrate measurably longer lifespans (Buettner, 
2012). While there is research that suggest religiosity might provide better coping 
mechanisms to manage symptoms of depression over time (Amadi et al., 2016) which 
may affect longitudinal studies examining conversion rates, the current study only 
examined cross-sectional results. Regardless of the unique characteristics of our sample, 






Abramson, L. Y., Metalsky, G. I., & Alloy, L. B. (1989). Hopelessness depression: A 
theory- based subtype of depression. Psychological Review, 96(2), 358-372. 
doi:10.1037/0033-295X.96.2.358 
 
Adams, K. B., Matto, H. C., & Sanders, S. (2004). Confirmatory Factor Analysis of 
 the Geriatric Depression Scale. The Gerontologist, 44(6), 818-826. 
 doi:10.1093/geront/44.6.818 
 
Albert, M. S., Moss, M. B., Tanzi, R., & Jones, K. (2001). Preclinical prediction of 
 AD using neuropsychological tests. Journal of the International 
 Neuropsychological Society, 7(5), 631-639.  doi:10.1017/S1355617701755105 
 
Alexopoulos, G. S., Raue, P. J., Kiosses, D. N., Mackin, R. S., Kanellopoulos, D., 
 McCulloch, C., & Areán, P. A. (2011). Problem-solving therapy and 
 supportive therapy in  older adults with major depression and executive 
 dysfunction. Archives of General Psychiatry, 68(1), 33-41. 
 doi:10.1001/archgenpsychiatry.2010.177 
 
Amadi, K. U., Uwakwe, R., Odinka, P. C., Ndukuba, A. C., Muomah, C. R., & Ohaeri, J. 
U. (2016). Religion, coping and outcome in out‐patients with depression or 
diabetes mellitus. Acta Psychiatrica Scandinavica, 133(6),  489-496. 
doi:10.1111/acps.12537 
 
Anstey, K. J., von Sanden, C., Sargent-Cox, K., & Luszcz, M. A. (2007). Prevalence 
 and risk factors for depression in a longitudinal, population-based study 
 including individuals in the community and residential care. The American 
 Journal of Geriatric Psychiatry, 15(6), 497-505. 
 doi:10.1097/JGP.0b013e31802e21d8 
 
Balthazar, M. L. F., Yasuda, C. L., Cendes, F., & Damasceno, B. P. (2010). Learning, 
retrieval, and recognition are compromised in aMCI and mild AD: Are distinct 
episodic memory processes mediated by the same anatomical structures? Journal 
of the International Neuropsychological Society, 16(1), 205-209. 
doi:10.1017/S1355617709990956 
 
Barnes, D. E., Yaffe, K., Byers, A. L., McCormick, M., Schaefer, C., & Whitmer, R. A. 
(2012). Midlife vs late-life depressive symptoms and risk of dementia: 
Differential effects for Alzheimer disease and vascular dementia. JAMA 
Psychiatry, 69(5), 493-498.  
 
Baune, B. T., Suslow, T., Arolt, V., & Berger, K. (2007). The relationship between 
psychological dimensions of depressive symptoms and cognitive functioning in 




Björklund, A., & Dunnett, S. B. (2007). Dopamine neuron systems in the brain: an 
update. Trends in Neurosciences, 30(5), 194-202. 
doi:https://doi.org/10.1016/j.tins.2007.03.006 
 
Brailean, A., Comijs, H. C., Aartsen, M. J., Prince, M., Prina, A. M., Beekman, A., & 
Huisman, M. (2016). Late-life depression symptom dimensions and cognitive 
functioning in the Longitudinal Aging Study Amsterdam (LASA).  Journal of 
Affective Disorders, 201, 171-178. doi:10.1016/j.jad.2016.05.027 
 
Brendel, M., Reinisch, V., Kalinowski, E., Levin, J., Delker, A., Därr, S., . . . Rominger, 
A. (2016). Hypometabolism in brain of cognitively normal patients with 
depressive symptoms is accompanied by atrophy-related partial volume effects. 
Current Alzheimer Research, 13(5), 475-486. 
doi:10.2174/1567205013666160314143922 
 
Brenes, G. A., Williamson, J. D., Messier, S. P., Rejeski, W. J., Pahor, M., Ip, E., & 
Penninx, B. W. J. H. (2007). Treatment of minor depression in older adults: A 
pilot study comparing sertraline and exercise. Aging & Mental Health, 11(1), 61-
68. doi:10.1080/13607860600736372 
 
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000). Risk factors for  suicide 
in psychiatric outpatients: A 20-year prospective study. Journal of  Consulting 
and Clinical Psychology, 68(3), 371-377. doi:10.1037/0022-006X.68.3.371 
 
Buettner, D. (2012). The blue zones: 9 lessons for living longer from the people who've 
lived the longest: National Geographic Books. 
 
Burgmans, S., van Boxtel, M. P. J., Smeets, F., Vuurman, E. F. P. M., Gronenschild, E. 
H. B. M., Verhey, F. R. J., . . . Jolles, J. (2009). Prefrontal cortex atrophy predicts 
dementia over a six-year period. Neurobiology of Aging, 30(9), 1413-1419. 
doi:https://doi.org/10.1016/j.neurobiolaging.2007.11.028 
 
Cargin, J. W., Collie, A., Masters, C., & Maruff, P. (2008). The nature of cognitive 
complaints in healthy older adults with and without objective memory decline. 
Journal of Clinical and Experimental Neuropsychology, 30(2), 1-13. 
doi:10.1080/13803390701377829 
 
Chisholm, D., Sanderson, K., Ayuso-Mateos, J. L., & Saxena, S. (2004). Reducing the 
global burden of depression: Population-level analysis of intervention cost-
effectiveness in 14 world regions. The British Journal of Psychiatry, 184(5), 393-
403. doi:10.1192/bjp.184.5.393 
 
Chiu, P.-Y., Tsai, C.-T., Chen, P.-K., Chen, W.-J., & Lai, T.-J. (2016). Neuropsychiatric 
symptoms in Parkinson’s disease dementia are more similar to Alzheimer’s 




Chopra, M. P., Zubritsky, C., Knott, K., Have, T. T., Hadley, T., Coyne, J. C., & Oslin, 
D. W. (2005). Importance of Subsyndromal Symptoms of Depression in Elderly 
Patients. The American Journal of Geriatric Psychiatry, 13(7), 597-606. 
doi:10.1176/appi.ajgp.13.7.597 
 
Cole, J., McGuffin, P., & Farmer, A. E. (2008). The classification of depression: Are we 
still confused? The British Journal of Psychiatry, 192(2), 83-85. 
doi:10.1192/bjp.bp.107.039826 
 
Corder, E. H., & Caskey, J. (2009). Early intervention in Alzheimer disease: The 
importance of APOE4 plus family history. Neurology, 73(24), 2054-2055. 
doi:10.1212/WNL.0b013e3181c67870 
 
Coutinho, G., Drummond, C., Teldeschi, A., & Mattos, P. (2016). Awareness of memory 
deficits is useful to distinguish between depression and mild cognitive impairment 
in the elderly. Revista Brasileira de Psiquiatria, 38(3), 231-234. 
doi:10.1590/1516-4446-2015-1772 
 
Cowen, P. J. (2010). Not fade away: The HPA axis and depression. Psychological 
Medicine, 40(1), 1-4. doi:10.1017/S0033291709005558 
 
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & 
Gornbein, J. (1994). Neuropsychiatric Inventory. 
 
Dean, J., & Keshavan, M. (2017). The neurobiology of depression: An integrated view. 
Asian J Psychiatr, 27, 101-111. doi:10.1016/j.ajp.2017.01.025 
 
Diagnostic and statistical manual of mental disorders: DSM-5™., 5th ed. (2013). 
Arlington, VA, US: American Psychiatric Publishing, Inc. 
 
Dillon, C., Machnicki, G., Serrano, C. M., Rojas, G., Vazquez, G., & Allegri, R. F. 
(2011). Clinical manifestations of geriatric depression in a memory clinic: 
Toward a proposed subtyping of geriatric depression. Journal of Affective 
Disorders, 134(1-3), 177-187. doi:10.1016/j.jad.2011.05.036 
 
Dranovsky, A., & Hen, R. (2006). Hippocampal Neurogenesis: Regulation by Stress and 
Antidepressants. Biological Psychiatry, 59(12), 1136-1143. 
doi:10.1016/j.biopsych.2006.03.082 
 
Driessen, E., & Hollon, S. D. (2010). Cognitive behavioral therapy for mood disorders: 
Efficacy, moderators and mediators. Psychiatric Clinics of North America, 33(3), 
537-555. doi:10.1016/j.psc.2010.04.005 
 
Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: potential 




Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: A practical 
method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatric Research, 12(3), 189-198. doi:10.1016/0022-3956(75)90026-6 
 
Förstl, H., Levy, R., Burns, A., Luthert, P., & Cairns, N. (1994). Disproportionate  loss of 
noradrenergic and cholinergic neurons as cause of depression in Alzheimer's 
disease: A hypothesis. Pharmacopsychiatry, 27(1), 11-15. doi:10.1055/s-2007-
1014267 
 
Gabryelewicz, T., Styczynska, M., Luczywek, E., Barczak, A., Pfeffer, A., Androsiuk, 
W., . . . Barcikowska, M. (2007). The rate of conversion of mild cognitive 
impairment to dementia: Predictive role of depression. International Journal of 
Geriatric Psychiatry, 22(6), 563-567. doi:10.1002/gps.1716 
 
Geda, Y. E., Roberts, R. O., Knopman, D. S., Petersen, R. C., Christianson, T. J. H., 
Pankratz, V. S., . . . Rocca, W. A. (2008). Prevalence of neuropsychiatric 
symptoms in mild cognitive impairment and normal cognitive aging: Population 
based study. Archives of General Psychiatry, 65(10), 1193-1198. 
doi:10.1001/archpsyc.65.10.1193 
 
Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J., & Schmand, B. (1999). 
Association between memory complaints and incident Alzheimer's  disease in 
elderly people with normal baseline cognition. The American Journal of 
Psychiatry, 156(4), 531-537.  
 
Ginó, S., Mendes, T., Maroco, J., Ribeiro, F., Schmand, B. A., de Mendonça, A., & 
Guerreiro, M. (2010). Memory complaints are frequent but qualitatively different 
in young and elderly healthy people. Gerontology, 56(3), 272-277. 
doi:10.1159/000240048 
 
Golden, C., Freshwater, S. M., & Golden, Z. (2002). Stroop Color and Word Test: 
Stoelting Co. 
 
Goldney, R. D., Fisher, L. J., Dal Grande, E., & Taylor, A. W. (2004). Subsyndromal 
depression: prevalence, use of health services and quality of life in an Australian 
population. Social Psychiatry and Psychiatric Epidemiology, 39(4), 293-298. 
doi:10.1007/s00127-004-0745-5 
 
Gonzales, M. M., Insel, P. S., Nelson, C., Tosun, D., Mattsson, N., Mueller, S. G., . . . 
Mackin, R. S. (2017). cortical atrophy is associated with accelerated cognitive 
decline in mild cognitive impairment with subsyndromal depression. The 
American Journal of Geriatric Psychiatry, 25(9), 980-991. 
doi:10.1016/j.jagp.2017.04.011 
 
Handley, T. E., Kay-Lambkin, F. J., Baker, A. L., Lewin, T. J., Kelly, B. J., Inder, K. J., . 
Kavanagh, D. J. (2013). Incidental treatment effects of CBT on suicidal ideation 
 
53 
and hopelessness. Journal of Affective Disorders, 151(1), 275-283. 
doi:10.1016/j.jad.2013.06.005 
 
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013). Alzheimer disease in the 
United States (2010–2050) estimated using the 2010 census. Neurology, 80(19), 
1778-1783. doi:10.1212/WNL.0b013e31828726f5 
 
Hinkelmann, K., Moritz, S., Botzenhardt, J., Riedesel, K., Wiedemann, K., Kellner, M., 
& Otte, C. (2009). Cognitive impairment in major depression: Association with 
salivary cortisol. Biological Psychiatry, 66(9), 879-885. 
doi:10.1016/j.biopsych.2009.06.023 
 
Huang, C.-W., Lui, C.-C., Chang, W.-N., Lu, C.-H., Wang, Y.-L., & Chang, C.-C. 
(2009). Elevated basal cortisol level predicts lower hippocampal volume and 
cognitive decline in Alzheimer’s disease. Journal of Clinical Neuroscience, 
16(10), 1283-1286.  
 
Hybels, C. F., Pieper, C. F., Blazer, D. G., & Steffens, D. C. (2016). Heterogeneity in the 
three‐year course of major depression among older adults. International Journal 
of Geriatric Psychiatry, 31(7), 775-782. doi:10.1002/gps.4391 
 
Jack, C. R., Jr., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Smith, G. E., Ivnik, R. J., . . . 
Kokmen, E. (1999). Prediction of AD with MRI-based hippocampal volume in 
mild cognitive impairment. Neurology, 52(7), 1397-1403. 
doi:10.1212/WNL.52.7.1397 
 
Jeon, H. J., Park, J.-I., Fava, M., Mischoulon, D., Sohn, J. H., Seong, S., . . . Cho, M. J. 
(2014). Feelings of worthlessness, traumatic experience, and their comorbidity in 
relation to lifetime suicide attempt in community adults with major depressive 
disorder. Journal of Affective Disorders, 166, 206-212. 
doi:10.1016/j.jad.2014.05.010 
 
João, A. A., Maroco, J., Ginó, S., Mendes, T., de Mendonça, A., & Martins, I. P. (2016). 
Education modifies the type of subjective memory complaints in older people. 
International Journal of Geriatric Psychiatry, 31(2), 153-160. 
doi:10.1002/gps.4305 
 
Kaplan, E., Goodglass, H., & Weintraub, S. (2001). Boston naming test: Pro-ed. 
 
Kondo, D., Ota, K., Kasanuki, K., Fujishiro, H., Chiba, Y., Murayama, N., . . . Iseki, E. 
(2016). Characteristics of mild cognitive impairment tending to convert into 
Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a 





Lavretsky, H., & Kumar, A. (2002). Clinically significant non-major depression: Old 
concepts, new insights. The American Journal of Geriatric Psychiatry, 10(3), 
239-255. doi:10.1176/appi.ajgp.10.3.239 
 
Lee, G. J., Lu, P. H., Hua, X., Lee, S., Wu, S., Nguyen, K., . . . Thompson, P. M. (2012). 
Depressive symptoms in mild cognitive impairment predict greater atrophy in 
Alzheimer's disease-related regions. Biological Psychiatry, 71(9), 814-821. 
doi:10.1016/j.biopsych.2011.12.024 
 
Lehrner, J., Kogler, S., Lamm, C., Moser, D., Klug, S., Pusswald, G., . . . Auff, E. (2015). 
Awareness of memory deficits in subjective cognitive decline, mild cognitive 
impairment, Alzheimer’s disease and Parkinson’s disease. International 
Psychogeriatrics, 27(3), 357-366. doi:10.1017/S1041610214002245 
 
Lester, D., & Walker, R. L. (2007). Hopelessness, helplessness, and haplessness as 
predictors of suicidal ideation. Omega: Journal of Death and Dying, 55(4), 321-
324. doi:10.2190/OM.55.4.f 
 
Lim, J., Oh, I. K., Han, C., Huh, Y. J., Jung, I.-K., Patkar, A. A., . . . Jang, B.-H. (2013). 
Sensitivity of cognitive tests in four cognitive domains in discriminating MDD 
patients from healthy controls: A meta-analysis. International Psychogeriatrics, 
25(9), 1543-1557. doi:10.1017/S1041610213000689 
 
Liu, R.-J., & Aghajanian, G. K. (2008). Stress blunts serotonin- and hypocretin-evoked 
EPSCs in prefrontal cortex: Role of corticosterone-mediated apical dendritic 
atrophy. PNAS Proceedings of the National Academy of Sciences of the United 
States of America, 105(1), 359-364. doi:10.1073/pnas.0706679105 
 
Luis, C. A., Barker, W. W., Loewenstein, D. A., Crum, T. A., Rogaeva, E., Kawarai, T., . 
. . Duara, R. (2004). Conversion to dementia among two groups with cognitive 
impairment. Dementia and Geriatric Cognitive Disorders, 18(3-4), 307-313. 
doi:10.1159/000080124 
 
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. 
(2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive 
impairment: Results from the Cardiovascular Health Study. JAMA: Journal of the 
American Medical Association, 288(12), 1475-1483. 
doi:10.1001/jama.288.12.1475 
 
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, 
J. C. S. (2000). Mental and behavioral disturbances in dementia: Findings from 
the Cache County Study on Memory in Aging. The American Journal of 
Psychiatry, 157(5), 708-714. doi:10.1176/appi.ajp.157.5.708 
 
Lyness, J. M., Chapman, B. P., McGriff, J., Drayer, R., & Duberstein, P. R. (2009). One-
year outcomes of minor and subsyndromal depression in older primary care 
 
55 
patients. International Psychogeriatrics, 21(1), 60-68. 
doi:10.1017/S1041610208007746 
 
Lyness, J. M., Kim, J., Tang, W., Tu, X., Conwell, Y., King, D. A., & Caine, E. D. 
(2007). The clinical significance of subsyndromal depression in older primary 
care patients. The American Journal of Geriatric Psychiatry, 15(3), 214-223. 
doi:10.1097/01.JGP.0000235763.50230.83 
 
Mackin, R. S., Insel, P., Aisen, P. S., Geda, Y. E., & Weiner, M. W. (2012). Longitudinal 
stability of subsyndromal symptoms of depression in individuals with mild 
cognitive impairment: Relationship to conversion to dementia after 3 years. 
International Journal of Geriatric Psychiatry, 27(4), 355-363.  
 
Mackin, R. S., Insel, P., Tosun, D., Mueller, S. G., Schuff, N., Truran-Sacrey, D., . . . 
Weiner, M. W. (2013). The effect of subsyndromal symptoms of depression and 
white matter lesions on disability for individuals with mild cognitive impairment. 
The American Journal of Geriatric Psychiatry, 21(9), 906-914. 
doi:10.1016/j.jagp.2013.01.021 
 
Manly, J. J., Tang, M.-X., Schupf, N., Stern, Y., Vonsattel, J.-P. G., & Mayeux, R. 
(2008). Frequency and course of mild cognitive impairment in a multiethnic 
community. Annals of Neurology, 63(4), 494-506. doi:10.1002/ana.21326 
 
McEwen, B. S., Eiland, L., Hunter, R. G., & Miller, M. M. (2012). Stress and anxiety: 
structural plasticity and epigenetic regulation as a consequence of stress. 
Neuropharmacology, 62(1), 3-12. doi:10.1016/j.neuropharm.2011.07.014 
 
Michelsen, K. A., Prickaerts, J., & Steinbusch, H. W. M. (2008). The dorsal raphe 
nucleus and serotonin: implications for neuroplasticity linked to major depression 
and Alzheimer's disease. Progress in Brain Research, 172, 233-264. 
doi:http://dx.doi.org/10.1016/S0079-6123(08)00912-6 
 
Modrego, P. J., & Ferrández, J. (2004). Depression in Patients With Mild Cognitive 
Impairment Increases the Risk of Developing Dementia of Alzheimer Type. 
Archives of Neurology, 61(8), 1290-1293. doi:10.1001/archneur.61.8.1290 
 
Morris, J. C., & Cummings, J. (2005). Mild cognitive impairment (MCI) represents early-
stage Alzheimer's disease. Journal of Alzheimer's Disease, 7(3), 235-239.  
 
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., . . . Padovani, 
A. (2004). MCI conversion to dementia and the APOE genotype A prediction 
study with FDG-PET. Neurology, 63(12), 2332-2340.  
 
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, 
I., . . . Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A Brief 
 
56 
Screening Tool For Mild Cognitive Impairment. Journal of  the American 
Geriatrics Society, 53(4), 695-699. doi:10.1111/j.1532-5415.2005.53221.x 
 
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006). Depression 
and Risk for Alzheimer Disease: Systematic Review, Meta-analysis, and 
Metaregression Analysis. Archives of General Psychiatry, 63(5), 530-538. 
doi:10.1001/archpsyc.63.5.530 
 
Oxman, T. E., Hegel, M. T., Hull, J. G., & Dietrich, A. J. (2008). Problem-solving 
treatment and coping styles in primary care for minor depression. Journal of 
Consulting and Clinical Psychology, 76(6), 933-943. doi:10.1037/a0012617 
 
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., . . . 
Winblad, B. (2001). Current concepts in mild cognitive impairment. Archives of 
Neurology, 58(12), 1985-1992. doi:10.1001/archneur.58.12.1985 
 
Petrides, M. (2002). The mid-ventrolateral prefrontal cortex and active mnemonic 
retrieval. Neurobiology of Learning and Memory, 78(3), 528-538. 
doi:10.1006/nlme.2002.4107 
 
Porta-Etessam, J., Tobaruela-González, J. L., & Rabes-Berendes, C. (2011). Depression 
in patients with moderate Alzheimer disease: A prospective observational cohort 
study. Alzheimer Disease and Associated Disorders, 25(4), 317-325. 
doi:10.1097/WAD.0b013e31820e7c45 
 
Powell, L. H., Shahabi, L., & Thoresen, C. E. (2003). Religion and spirituality: Linkages 
to physical health. American Psychologist, 58(1), 36-52. doi:10.1037/0003-
066X.58.1.36 
 
Reitan, R. M., & Wolfson, D. (1986). The Halstead-Reitan Neuropsychological Test 
Battery.  
 
Rey, A. (1958). Rey Auditory Verbal Learning Test: Western Psychological Services. 
 
Rey, A., & Osterrieth, P. A. (1941). Rey-Osterrieth Complex Figure Copying Test. 
 
Ross, T. P., Calhoun, E., Cox, T., Wenner, C., Kono, W., & Pleasant, M. (2007). The 
reliability and validity of qualitative scores for the Controlled Oral Word 
Association Test. Archives of Clinical Neuropsychology, 22(4), 475-488. 
doi:10.1016/j.acn.2007.01.026 
 
Royall, D. R., Palmer, R., Chiodo, L. K., & Polk, M. J. (2012). Depressive symptoms 
predict longitudinal change in executive control but not memory. International 




Royall, D. R., & Palmer, R. F. (2013). Alzheimer's disease pathology does not mediate 
the association between depressive symptoms and subsequent cognitive decline. 
Alzheimer's & Dementia, 9(3), 318-325. 
doi:https://doi.org/10.1016/j.jalz.2011.11.009 
 
Rozzini, L., Chilovi, B. V., Trabucchi, M., & Padovani, A. (2005). Depression Is 
Unrelated to Conversion to Dementia in Patients With Mild Cognitive 
Impairment. Archives  of Neurology, 62(3), 505-505. 
doi:10.1001/archneur.62.3.505-a 
 
Schoenberg, M. R., & Scott, J. G. (2011). The little black book of neuropsychology: A 
syndrome-based approach. New York, NY, US: Springer Science + Business 
Media. 
 
Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, 
R. C., . . . Trojanowski, J. Q. (2009). Cerebrospinal fluid biomarker signature in 
Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 65(4), 
403-413. doi:10.1002/ana.21610 
 
Starkman, M. N., Gebarski, S. S., Berent, S., & Schteingart, D. E. (1992).  Hippocampal 
formation volume, memory dysfunction, and cortisol levels in patients with 
Cushing's syndrome. Biological Psychiatry, 32(9), 756-765. doi:10.1016/0006-
3223(92)90079-F 
 
Starkstein, S. E., Jorge, R., Mizrahi, R., & Robinson, R. G. (2005). The Construct of 
Minor and Major Depression in Alzheimer's Disease. The American Journal of 
Psychiatry, 162(11), 2086-2093. doi:10.1176/appi.ajp.162.11.2086 
 
Tabert, M. H., Manly, J. J., Liu, X., Pelton, G. H., Rosenblum, S., Jacobs, M., . . . 
Devanand, D. P. (2006). Neuropsychological Prediction of Conversion to 
Alzheimer Disease in Patients With Mild Cognitive Impairment. Archives of 
General Psychiatry, 63(8), 916-924. doi:10.1001/archpsyc.63.8.916 
 
Tadić, A., Helmreich, I., Mergl, R., Hautzinger, M., Kohnen, R., Henkel, V., & Hegerl, 
U. (2010). Early improvement is a predictor of treatment outcome  in patients 
with mild major, minor or subsyndromal depression. Journal of Affective 
Disorders, 120(1-3), 86-93. doi:10.1016/j.jad.2009.04.014 
 
Teng, E., Lu, P. H., & Cummings, J. L. (2007). Neuropsychiatric symptoms are 
associated with progression from mild cognitive impairment to Alzheimer's 
disease. Dementia and Geriatric Cognitive Disorders, 24(4), 253-259. 
doi:10.1159/000107100 
 
Turner, A. D., Capuano, A. W., Wilson, R. S., & Barnes, L. L. (2015). Depressive 
symptoms and cognitive decline in older African Americans: Two scales and their 
 
58 
factors. The American Journal of Geriatric Psychiatry, 23(6), 568-578. 
doi:10.1016/j.jagp.2014.08.003 
 
Van der Mussele, S., Bekelaar, K., Le Bastard, N., Vermeiren, Y., Saerens, J., Somers, 
N., . . . Engelborghs, S. (2013). Prevalence and associated behavioral symptoms 
of depression in mild cognitive impairment and dementia due to Alzheimer's 
disease. International Journal of Geriatric  Psychiatry, 28(9), 947-958. 
doi:10.1002/gps.3909 
 
Wang, B., Wang, Y., Wu, Q., Huang, H. P., & Li, S. (2017). Effects of alpha2A 
Adrenoceptors on Norepinephrine Secretion from the Locus Coeruleus during 
Chronic Stress-Induced Depression. Front Neurosci, 11, 243. 
doi:10.3389/fnins.2017.00243 
 
Wechsler, D. (2008). Wechsler Adult Intelligence Scale--Fourth Edition: Pearson. 
Wechsler Memory Scale--Fourth Edition. (2009). Pearson. 
 
Woo, S. L., Prince, S. E., Petrella, J. R., Hellegers, C., & Doraiswamy, P. M. (2009). 
Modulation of a human memory circuit by subsyndromal depression in late life: A 
functional magnetic resonance imaging study. The American Journal of Geriatric 
Psychiatry, 17(1), 24-29. doi:10.1097/JGP.0b013e318180056a 
 
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, O. 
(1983). Geriatric Depression Scale. 
 
Zubenko, G. S., & Moossy, J. (1988). Major depression in primary dementia: Clinical 
and neuropathologic correlates. Archives of Neurology, 45(11), 1182-1186. 
doi:10.1001/archneur.1988.00520350020008 
 
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., . . 
. Price, D. L. (1988). The neuropathology of aminergic nuclei in Alzheimer's 
disease. Annals of Neurology, 24(2), 233-242.  
 
 
 
